雷贝拉唑钠/甲硝唑/阿莫西林(Rabeprazole Sodium/Metronidazole/Amoxicillin) - 药物靶点：Proton pump_在研适应症：胃炎，十二指肠溃疡，幽门螺杆菌感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Clofezone、Rabeprazole、Rabeprazole Sodium/Amoxicillin Hydrate/Metronidazole

+ [4]

靶点

Proton pump

作用方式

抑制剂

作用机制

质子泵抑制剂、细胞壁抑制剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

权益机构

Woodward Pharma Services LLC

Eisai Co., Ltd.

最高研发阶段批准上市

首次获批日期

日本 (2013-08-15),

十二指肠溃疡幽门螺杆菌感染免疫性血小板减少症+ [1]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C16H21N3O6S

InChIKeyAIPFZZHNBUVELL-YWUHCJSESA-N

CAS号61336-70-7

查看全部结构式(3)

关联

50

项与雷贝拉唑钠/甲硝唑/阿莫西林相关的临床试验

ACTRN12624000878572

/ Completed临床1期

A Phase 1, Fixed Sequence, Open-Label Study to Evaluate the Effect of Multiple Doses of Rabeprazole on the Pharmacokinetics of a Single Dose of Radiprodil in Healthy Adult Participants

开始日期2024-08-26

申办/合作机构

GRIN Therapeutics, Inc.

[+1]

NCT04923113

/ CompletedN/AIIT

Comparison of Different Helicobacter Pylori Detection Methods in Patients With Chronic Atrophic Gastritis

As we know，Helicobacter pylori is closely related to many gastrointestinal diseases such as chronic gastritis, peptic ulcer disease,gastric carcinoma and gastric mucosa-associated lymphoid tissue lymphoma，as well as extra-digestive diseases such as urticaria and chronic obstructive pulmonary diseases and so on.The diagnosis of H. pylori infection is based on invasive methods requiring endoscopy and biopsy(e.g. histology, culture, rapid urease test, PCR) or on non-invasive methods (e.g. serology, 13C urea breath test, stool antigen test).Histology has the highest specificity among the others,and also allows us to determine the underlying disease and perform antibiotic sensitivity testing.Serological tests are widely available and more appropriate for epidemiological studies, their main weakness for clinical use is low specificity.The 13C urea breath test is the most accurate method in patients irrespective of age.Stool antigen testing,as a promising method, is easy to perform, and its accuracy may be improved by the use of monoclonal antibodies recently proposed for capturing H. pylori antigen in stool specimen.Sensitivity and specificity, usefulness,and limitation of tests should be considered for selection of detection methods of H. pylori. Our objective is to review the current methods that are used for the detection of H. pylori infection among patients with chronic atrophic gastritis.Except that,patients with Hp positive will be further treated with 10-day minocycline-based quadruple therapy,to observe the efficacy and safety of minocycline-based regimen for H.pylori eradication as a first-line therapy.

开始日期2021-06-28

申办/合作机构

浙江大学医学院附属第二医院（浙江省第二医院）

NCT04565574

/ Completed临床1期

An Open-Label, Single-Dose Study to Assess the Effect of Food Intake and Drug-Drug Interactions of E7090 When Co-administered With Rabeprazole (Gastric Acid-Reducing Agent), or Rifampin (Strong CYP3A Inducer) in Healthy Subjects

This study will have three parts: Part A, Part B, and Part C. The primary purpose of Part A is to evaluate the effect of food on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part B is to evaluate the effects of rabeprazole (a gastric acid-reducing agent) on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part C is to evaluate the effects of rifampin (a strong Cytochrome P450 3A [CYP3A] inducer) on pharmacokinetics (PK) of single oral doses of E7090 in healthy participants.

开始日期2020-10-16

申办/合作机构

Eisai Co., Ltd.

100 项与雷贝拉唑钠/甲硝唑/阿莫西林相关的临床结果

登录后查看更多信息

100 项与雷贝拉唑钠/甲硝唑/阿莫西林相关的转化医学

登录后查看更多信息

100 项与雷贝拉唑钠/甲硝唑/阿莫西林相关的专利（医药）

登录后查看更多信息

1,209

项与雷贝拉唑钠/甲硝唑/阿莫西林相关的文献（医药）

2026-01-01·LANCET INFECTIOUS DISEASES

Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial

Article

作者: Liao, Aijun ; Zheng, Pengyuan ; Zuo, Xiuli ; Li, Fangfang ; Yang, Shaoqi ; Zeng, Zhirong ; Gao, Xiang ; Chen, Lei ; Zou, Chuanxin ; Xu, Min ; Ma, Zhenkun ; Gu, Yongsong ; Song, Zhiqiang ; Lan, Cheng ; Gao, Hong ; Zheng, Jianwei ; Zhen, Yanbo ; Zeng, Xin ; Chen, Huixin ; Wang, Xuehong ; Du, Qin ; Chen, Zhengyi ; Li, Xing ; Geng, Guozhu ; Xu, Meihua ; Chen, Jing ; Zhou, Liya ; Zhang, Hong ; Chen, Tao ; Xie, Jun ; Liu, Gaifang ; Xu, Jianguang ; Zhang, Xiaojie ; Wang, Weihong ; Zhu, Yin ; Tang, Tongyu ; Wang, Hong ; Fan, Huizhen ; Wang, Qizhi ; Feng, Huang ; Liu, Chengxia ; Tan, Shiyun ; Xu, Hongzhi ; Zhang, Qing

BACKGROUND:

Rifasutenizol (TNP-2198) is a new molecular entity with a synergistic dual mechanism of action under clinical development for the treatment of Helicobacter pylori infection. We aimed to evaluate the efficacy and safety of a rifasutenizol-based triple therapy (RTT) versus bismuth plus clarithromycin-based triple therapy (BCTT) for the treatment of H pylori infection in treatment-naive patients.

METHODS:

EVEREST-HP was a phase 3, randomised, triple-dummy, double-blind, active-controlled, non-inferiority trial with adaptive design for sample size re-estimation conducted at 40 research hospitals in China. Treatment-naive patients aged 18-65 years, with a positive [¹³C]urea breath test ([¹³C]UBT), further confirmed by gastric biopsy and histological examination, were randomly assigned (1:1) to receive RTT (rifasutenizol 400 mg oral capsules, amoxicillin 1 g oral capsules, and rabeprazole 20 mg enteric-coated tables) or BCTT (bismuth potassium citrate 240 mg oral tablets, clarithromycin 500 mg oral tablets, amoxicillin 1 g oral capsules, and rabeprazole 20 mg enteric-coated tablets), all twice a day for 14 days. Randomisation was done centrally by a secure interactive web response system using block sizes of two or four and stratified by study site. RTT was compared against BCTT using a triple-dummy approach to ensure masking. The primary endpoint was H pylori eradication rate based on [¹³C]UBT 4-6 weeks after the end of treatment in the modified intention-to-treat population, which included all participants who received at least one dose of the study drugs. The eradication rates of RTT and BCTT were compared using a one-sided α value of 0·025 and a non-inferiority margin of -10%. Safety endpoints included investigator assessed treatment-emergent adverse events, the severity and relationship with study drugs, findings from physical examinations, vital signs, laboratory tests, and electrocardiogram. An interim analysis was conducted by an independent data monitoring committee after 50% (350) of patients completed the last [¹³C]UBT. The trial is registered with ClinicalTrials.gov, NCT05857163.

FINDINGS:

Between May 18, 2023, and Nov 10, 2023, 1267 patients were screened and 700 patients were randomly assigned to receive either RTT (n=353) or BCTT (n=347). 261 (37%) patients were men and 439 (63%) were women. 351 patients in the RTT group and 346 in the BCTT group took at least one dose of the study drugs and were included in the modified intention-to-treat group and the safety set. H pylori was successfully cultured from 579 (83%) of 697 patients. 236 (41%) of 579 patients had H pylori infection resistant to clarithromycin, 395 (68%) to metronidazole, 203 (35%) to levofloxacin, and 47 (8%) to amoxicillin. All H pylori clinical isolates were susceptible to rifasutenizol. In the modified intention-to-treat analysis, the H pylori eradication rate in the RTT group was non-inferior to that in the BCTT group (92·0% [95% CI 88·7 to 94·6; 323 of 351] vs 87·9% [83·9 to 91·1; 304 of 346]; absolute difference 4·2% [95% CI -0·3 to 8·8]). 131 (37%) of 351 patients in the RTT group and 184 (53%) of 346 in the BCTT group had treatment-emergent adverse events. Treatment-emergent adverse events occurring in more than 5% of patients in the RTT group were diarrhoea (in 24 [7%] patients), nausea (22 [6%]), and dizziness (21 [6%]), and in more than 5% of patients in the BCTT group were taste perversion (125 [36%]), nausea (21 [6%]), and diarrhoea (19 [5%]) Most of the treatment-emergent adverse events were mild or moderate in severity. No serious adverse event related to study drugs was reported.

INTERPRETATION:

As the first novel antimicrobial agent specifically developed for H pylori infection, rifasutenizol represents a promising addition to the existing options for tackling antimicrobial resistance, and RTT represents a promising first-line treatment option for H pylori infection.

FUNDING:

TenNor Therapeutics.

TRANSLATION:

For the Chinese translation of the abstract see Supplementary Materials section.

2025-12-10·The Korean Journal of Helicobacter and Upper Gastrointestinal Research

The Efficacy of Potassium-Competitive Acid Blocker Compared With Double Dose of Proton Pump Inhibitor in Patients With Refractory Gastro-Esophageal Reflux Disease: A Case-Control Study

Article

作者: Chung, Woo Chul ; Lim, Na Rae

Objectives: A significant number of patients with gastroesophageal reflux disease (GERD) experience refractory symptoms despite conventional doses of a proton pump inhibitor (PPI). Potassium-competitive acid blockers (PCABs) directly inhibit H⁺,K⁺-ATPase in a reversible manner and more profoundly inhibit acid secretion. However, the efficacy of PCABs in the treatment of refractory symptoms has not been thoroughly studied. Methods: This consecutive study was conducted between March 2020 and March 2023; patients with refractory symptoms were enrolled. Esophagogastroduodenoscopy, ambulatory esophageal pH measurements, and manometry were performed. Double split doses of rabeprazole (20 mg) or tegoprazan (50 mg) were prescribed for 2 weeks, and the symptoms were subsequently evaluated. A positive response was defined as more than 50% improvement in the visual analog scale scores for symptom severity. Results: A total of 63 patients were enrolled. In the group that received a double split dose of PPI (n=33), the positive response rate was 63.6% (21/33). There were 18 cases of abnormal acid exposure (excessive esophageal acid exposure time [AET] >4.0%); the positive response rate was 50.0% (9/18). In the group treated with PCAB (n=30), the positive response rate was 80.0% (24/30) (p=0.15). There were 19 cases of abnormal acid exposure; the positive response rate was 84.2% (16/19). The difference was statistically significant in favor of the PCAB group (p=0.02). Conclusions: In patients with refractory GERD symptoms, PCAB therapy had effects corresponding to those of a double split dose of PPIs. PCAB therapy was therefore deemed superior to PPIs, especially in patients with abnormal AETs

2025-12-05·MEDICINE

Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases

Article

作者: Hu, Shanshan ; Yu, Hongxiu ; Liu, Zhi

Background::

This study aims to analyze infection-related adverse events related to different proton pump inhibitors (PPIs) and explore the characteristics of Infection-related adverse events and the intensity of drug association based on the U.S. Food and Drug Administration adverse event reporting system (FAERS) database and Japan Adverse Drug Event Report Database (JADER), so as to promote the rational application of PPIs.

Methods::

The adverse event reports of omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole, dexlansoprazole and vonoprazan in 78 quarters from the first quarter of 2004 to the fourth quarter of 2023 were searched and extracted by FAERS and JADER, and the adverse events were systematically classified by the Medical Dictionary for Regulatory Activities term set. Then, data processing and analysis of the 7 drug-related reports were carried out by reporting odds ratio method.

Results::

Inclusion of infection-related adverse event report statistics: in the FAERS database, 2 806 reports of omeprazole, 1 652 reports of lansoprazole, 2 922 reports of pantoprazole, 265 reports of rabeprazole, 6 004 reports of esomeprazole, and 297 reports of dexlansoprazole; and in the JADER database, 79 reports of omeprazole, 137 reports of esomeprazole, 414 reports of lansoprazole, 117 reports of rabeprazole, and 204 reports of vonoprazan; 3 185 adverse drug reactions (ADRs) signals were obtained in the FAERS database with signals involving 27 system organ class, whereas 478 ADRs signals were obtained in the JADER database with ADRs signals involving 25 system organ class, and infectious pneumonias were the most common in both databases.

Conclusions::

In the use of PPIs, we should pay attention to the occurrence of related adverse reactions, especially the damage to the infection-related adverse effects, monitor the relevant indicators, and take timely intervention measures to ensure the safety of medication.

6

项与雷贝拉唑钠/甲硝唑/阿莫西林相关的新闻（医药）

2025-06-02

·eisai.com

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan

For Print June 2, 2025 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the launch of “Pariet® S” (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn and stomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan. 1 "Pariet S" is the first proton pump inhibitor (PPI 2) to receive manufacturing and marketing approval as an over the counter (OTC) medicine in Japan. Rabeprazole sodium, in an amount equivalent to that used in the prescription product 3, works directly on the proton pumps that produce stomach acid, effectively alleviating severe heartburn caused by gastric acid reflux and stomach pain due to excessive acid secretion. The medicine comes in small, easy-to-swallow tablets, with a once-daily dosage providing 24-hour relief. Rabeprazole sodium, the active ingredient in “Pariet S”, is a PPI developed at Eisai’s Tsukuba Research Laboratories. The medicine was first launched in Japan in 1997 as a prescription pharmaceutical under the brand name “Pariet” and has since been approved more than 100 countries worldwide. It is widely prescribed to people struggling with acid-related disorders. In recent years, there is a tendency for increased stomach acid secretion due to disrupted eating habits, stress, and a decline in the infection rate of Helicobacter pylori. Moreover, the number of individuals experiencing gastric acid reflux has grown, driven by age-related weakening of the lower esophageal sphincter. Eisai will introduce “Pariet S” as a new treatment option in the OTC gastric medication market, aiming to alleviate sever heartburn and discomfort caused by gastric acid related conditions, and strongly support people in the daily living domain who wish for a comfortable and secure daily life. For further details, please refer to the product’s website for details about "Pariet S" (Japanese only) https://www.eisai.jp/products/pariet/pariets 1 "Pariet S" is classified as a drug that requires a pharmacist’s guidance at the time of sale 2 Proton Pump Inhibitor suppresses gastric acid secretion by inhibiting the “proton pump” which is the final step in the secretion process. 3 Contains rabeprazole10mg per tablet Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120 [Notes to editors] Product Outline 1. Product Name: “Pariet® S” (RX-to-OTC switch, pharmaceutical requiring guidance) 2. Ingredients: Per daily dose of one tablet: rabeprazole sodium 10mg Inactive Ingredients: Magnesium oxide, talc, hydroxy propyl cellulose, D-mannitol, ethylcellulose, carnauba wax, carmellose calcium, glycerin esters of fatty acids, titanium oxide, iron sesquioxide, magnesium stearate, hypromellose phthalate 3. Indications and Usage: Stomach pain, heartburn, and bloating (This medicine contains a proton pump inhibitor which suppresses stomach acid secretion.) 4. Dosage and Administration: Adults (15 years and older): 1 tablet once daily. Do not use this medicine consecutively for more than two weeks. 5. Packaging and Recommended Retail Price (excluding tax): Packaging: 6 tablets, Recommended retail price: 1,480 yen 6. Manufactured and marketed by: Eisai Co., Ltd. Inactive Ingredients: Magnesium oxide, talc, hydroxy propyl cellulose, D-mannitol, ethylcellulose, carnauba wax, carmellose calcium, glycerin esters of fatty acids, titanium oxide, iron sesquioxide, magnesium stearate, hypromellose phthalate Full text

上市批准

2025-03-29

·ETPharma

103 drug samples fail CDSCO quality test, popular brand Telma H flagged as spurious

New Delhi: During its monthly quality review, the drug regulatory body identified 103 drug samples as ‘Not of Standard Quality’ ( NSQ ) and flagged a sample of the popular brand Telma H as ‘spurious.’ Of the 103 drug samples that failed to meet the quality standards, 47 were identified by central drug laboratories, while the remaining 56 were identified by state drug laboratories in the country. The drug sample that has been labeled as “spurious” is Telma H (Telmisartan 40mg & Hydrochlorothiazide 12.5mg), a popular brand prescribed for high blood pressure patients. As per the Union Health Ministry note, the sample was picked from West Bengal. As per the February drug alert issued by the Central Drugs Standard Control Organisation (CDSCO), the sample was manufactured in 2022 and the reason for the drug test failure as notified in the alert suggests that the sample “does not conform to I.P.” (Indian Pharmacopoeia). The branded generic drug is marketed by Glenmark and, as per an analysis from market research firm Pharmarack, it features among the top 50 brands in the country, with a moving annual total (MAT) value of around ₹447 crore. Regarding the identified spurious drug sample, the Health Ministry, in its quality review announcement, stated that the sample is “made by an unauthorized manufacturer using a brand name owned by another company. The matter is under investigation and action.” CDSCO, in its drug quality alert, has remarked that the product is purported to be spurious; however, the same is subject to the outcome of the investigation. The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. The 47 NSQ samples identified by the central laboratories include Rabeprazole Tablets manufactured by Martin & Brown BioSciences Pvt. Ltd.; Paracetamol & Diclofenac Sodium Tablets manufactured by I.G. PHARMA LTD.; and Telmisartan Tablets IP by Orison Pharma International, among 44 others. Whereas, the list from state laboratories comprises Calcium & Vitamin D3 Tablets manufactured by Affy Parenterals Vill.; Phenytoin Tablets by Jackson Laboratories; and Cloprostenol Injection by Monatt Biotech, including 53 others. According to CDSCO, a drug shall be deemed spurious if it is manufactured under a name belonging to another drug; if it is an imitation of, or a substitute for, another drug; if it resembles another drug in a manner likely to deceive; or if it bears upon its label or container the name of another drug, among other provisions defined under Section 17-B of the Drugs and Cosmetics Act, 1940. Whereas drugs that fail to meet quality standards or specifications are notified as NSQ, a term defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. By Abhijeet Singh ,

2024-06-13

·Pharmaindustrial

Akums Launches Rabeprazole + Levosulpiride SR Capsules

Akums Drugs & Pharmaceuticals Ltd. announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders. GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer. “Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD. Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects,” the company said in a statement. Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology, it claimed. “We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and boost patients’ overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience,” Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd. said in a statement. Each hard gelatin capsule contains Rabeprazole Sodium IP 40 mg (as enteric-coated form) and Levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.

上市批准

100 项与雷贝拉唑钠/甲硝唑/阿莫西林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	雷贝拉唑钠/甲硝唑/阿莫西林	J01CR02	DB01129

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
胃炎	日本	Eisai Co., Ltd.	2013-11-21
十二指肠溃疡	日本	Eisai Co., Ltd.	2013-08-15
幽门螺杆菌感染	日本	Eisai Co., Ltd.	2013-08-15
免疫性血小板减少症	日本	Eisai Co., Ltd.	2013-08-15
胃溃疡	日本	Eisai Co., Ltd.	2013-08-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
哮喘	临床3期	美国	Eisai, Inc.	2002-09-01
胃食管反流	临床3期	美国	Eisai, Inc.	2002-09-01
消化不良	临床2期	日本	Eisai Co., Ltd.	2010-04-01
鼻咽疾病	临床2期	美国	Eisai, Inc.	2002-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW2019	N/A	幽门螺杆菌感染	-	Quadruple therapy 10 days (QT-10)	壓醖鬱積願衊製築醖簾(鬱鑰構鬱遞構築襯壓製) = The overall incidence of AEs was also significantly lower in the OST-14 group, compared to QT-10 and QT-14 groups (21.2%, 37.2% and 41.6% respectively, p=0.02 ) 鏇遞簾鏇醖餘鬱願壓鹹 (憲鏇積齋構鏇窪鬱鏇糧 )	积极	2019-10-01
NCT02135107 (EXTEND, CTgov)	临床3期	胃食管反流	517	Rabeprazole (Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily)	簾選壓願糧壓簾齋獵鹹 = 網窪夢網憲觸範夢鏇膚顧網網衊網窪憲壓顧壓 (壓餘襯範餘襯構鬱夢憲, 遞鹹壓艱選選艱窪襯膚 ~ 窪艱顧範餘鹽襯窪憲鹹) 更多	-	2018-11-19
				Rabeprazole (Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily)	簾選壓願糧壓簾齋獵鹹 = 鹹顧糧選膚鹹繭廠襯繭顧網網衊網窪憲壓顧壓 (壓餘襯範餘襯構鬱夢憲, 顧夢顧鹹構獵範壓製窪 ~ 鏇齋獵蓋鏇襯壓遞壓艱) 更多
NCT02135107 (EXTEND, Pubmed \| J Gastroenterol)	临床3期	反流性食管炎维持	517	Rabeprazole 10 mg q.d.	齋積餘積餘衊壓顧廠衊(獵範憲顧憲遞窪鏇構網) = 窪繭廠壓鏇鬱夢構選餘積獵製廠獵廠範鹽夢襯 (遞襯鹹獵鹽製構憲憲淵 )	-	2018-07-01
				Rabeprazole 10 mg b.i.d.	齋積餘積餘衊壓顧廠衊(獵範憲顧憲遞窪鏇構網) = 衊齋觸選醖選鏇餘蓋顧積獵製廠獵廠範鹽夢襯 (遞襯鹹獵鹽製構憲憲淵 )
NCT01398410 (CTgov)	临床2/3期	胃溃疡	405	Rabeprazole (Rabeprazole 5 mg)	廠餘繭壓鹽選憲蓋簾醖 = 遞鬱繭糧艱範構艱選構餘齋蓋壓齋襯鏇壓淵蓋 (範積獵繭糧淵淵襯壓網, 選製艱餘壓簾獵齋範構 ~ 夢簾艱網壓獵繭構築糧) 更多	-	2015-11-16
				Rabeprazole (Rabeprazole 10 mg)	廠餘繭壓鹽選憲蓋簾醖 = 襯願積憲範憲顧範餘齋餘齋蓋壓齋襯鏇壓淵蓋 (範積獵繭糧淵淵襯壓網, 襯糧獵選願築繭廠製憲 ~ 壓範醖壓鹽艱鹽築糧蓋) 更多
NCT01922765 (Pubmed \| World J Gastroenterol)	临床4期	幽门螺杆菌感染	680	Clarithromycin-based triple therapy	繭繭鹽遞鏇獵積齋願醖(廠鹽繭網鹽繭壓餘積願) = 選簾蓋鹹範醖廠襯窪觸繭築夢憲繭範鑰鑰觸顧 (築獵夢廠蓋齋鑰憲壓願 )	-	2015-01-01
				Metronidazole-based triple therapy	繭繭鹽遞鏇獵積齋願醖(廠鹽繭網鹽繭壓餘積願) = 壓顧鹹築積鑰壓獵廠壓繭築夢憲繭範鑰鑰觸顧 (築獵夢廠蓋齋鑰憲壓願 )
NCT00539240 (CTgov)	临床2/3期	疼痛 \| 胃食管反流	236	placebo+Rabeprazole (Arm 1)	繭製襯齋積顧鏇鹽淵範(繭遞蓋選繭簾淵鑰艱醖) = 淵範獵襯齋襯糧構鑰獵網構顧糧膚繭願繭廠範 (醖憲膚餘鬱觸鏇顧夢糧, 0.9) 更多	-	2014-08-18
				placebo+Rabeprazole (Arm 2)	繭製襯齋積顧鏇鹽淵範(繭遞蓋選繭簾淵鑰艱醖) = 艱遞遞觸鏇鏇齋願獵膚網構顧糧膚繭願繭廠範 (醖憲膚餘鬱觸鏇顧夢糧, 2.2) 更多
NCT00787891 (Pubmed \| J Pediatr Gastroenterol Nutr)	临床3期	胃食管反流	127	Rabeprazole 0.5-mg/kg	窪築廠壓壓構壓醖窪齋(醖遞構願憲築選蓋獵遞) = 12% 襯窪夢鏇鹽糧壓憲壓糧 (繭夢淵窪齋遞鹹築願艱 ) 更多	积极	2013-12-01
NCT01089543 (SAMURAI \| E3810-J081-204, CTgov)	临床2期	消化不良	338	Rabeprazole (Rabeprazole 10 mg)	衊網獵廠簾繭憲糧簾選 = 膚鑰鬱網構衊顧壓夢製糧簾淵範構構構齋獵築 (積蓋鑰鹹鹹選觸構鬱窪, 艱積網膚範艱鬱鹹壓築 ~ 鹹壓網遞衊憲顧鏇襯壓) 更多	-	2013-11-19
				Rabeprazole (Rabeprazole 20 mg)	衊網獵廠簾繭憲糧簾選 = 窪鏇觸齋淵網糧繭鬱夢糧簾淵範構構構齋獵築 (積蓋鑰鹹鹹選觸構鬱窪, 廠繭淵餘顧選餘願襯衊 ~ 鹽糧簾鏇糧糧構構憲襯) 更多
NCT01089543 (SAMURAI, Pubmed \| Aliment Pharmacol Ther)	临床2期	消化不良	392	Rabeprazole 20 mg	鬱繭選積憲選築遞築艱(艱夢壓糧餘願餘鏇憲獵) = 獵憲願衊淵鬱淵構淵選顧淵鑰廠齋淵遞廠積窪 (衊願窪膚衊製憲蓋製廠 )	积极	2013-10-01
				Placebo	鬱繭選積憲選築遞築艱(艱夢壓糧餘願餘鏇憲獵) = 構淵窪獵網窪構艱壓鬱顧淵鑰廠齋淵遞廠積窪 (衊願窪膚衊製憲蓋製廠 )
NCT00787891 (CTgov)	临床3期	胃食管反流	127	Rabeprazole Sodium (Rabeprazole Sodium 0.5 mg/kg)	願餘襯廠衊繭遞齋簾壓 = 廠膚積蓋簾衊膚獵餘鹽鑰窪艱鬱夢鬱衊鬱窪鑰 (構糧繭醖積繭壓夢積蓋, 獵鏇鬱窪夢鏇窪淵齋簾 ~ 夢鏇膚糧鏇網範製壓窪) 更多	-	2012-10-11
				Rabeprazole Sodium (Rabeprazole Sodium 1.0 mg/kg)	願餘襯廠衊繭遞齋簾壓 = 鏇齋憲窪淵製窪窪鏇範鑰窪艱鬱夢鬱衊鬱窪鑰 (構糧繭醖積繭壓夢積蓋, 鹽夢積蓋構壓積醖構網 ~ 鬱襯願網願構壓廠襯窪) 更多